Study to Assess Cancer Patients' Satisfaction With Hospital Quality of Care
NCT ID: NCT00045019
Last Updated: 2012-08-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
795 participants
OBSERVATIONAL
2002-05-31
2005-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PURPOSE: Clinical trial to determine the effectiveness of questionnaires in assessing cancer patients' satisfaction with the quality of care they received in the hospital.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Determine the scale structure, reliability, and validity of the QLQ-SAT32 patient satisfaction module in assessing the perception of the quality of care received in hospitals by patients with cancer.
* Determine the success of the QLQ-SAT32 patient satisfaction module when used with the QLQ-C30 core quality of life questionnaire, in terms of expanding on quality of life evaluation or providing information on treatment acceptability or preference of these patients.
OUTLINE: This is a descriptive, multicenter study. Patients are stratified according to age (18 to 49 vs 50 and over) and the cancer therapy received in hospital (surgery vs chemotherapy).
Patients in all strata receive the QLQ-SAT32 and QLQ-C30 questionnaires, a debriefing questionnaire, and the Oberst patient satisfaction visual analog scale prior to hospital discharge. Patients complete the materials at home within 7 days of discharge. A group of 100 patients have a repeat QLQ-SAT32 module mailed to them to be completed within 7 days of receipt of first questionnaire.
PROJECTED ACCRUAL: A total of 640-768 patients (160-192 per stratum) will be accrued for this study.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
discharged cancer patients
patients discharged from a surgery or medical ward of oncology institutes in Belgium, France, Germany, Italy, Poland, Spain, Sweden, Taiwan and United Kingdom (as part of a larger psychometric validation study) were asked to rate there level of satisfaction, using the EORTC QLQ-SAT32.
quality-of-life assessment
QLQ-C30 SAT32
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
quality-of-life assessment
QLQ-C30 SAT32
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Histologically confirmed cancer
* Hospitalization of at least 3 days
* No clinical evidence of brain metastases
PATIENT CHARACTERISTICS:
Age
* 18 and over
Performance status
* Not specified
Life expectancy
* Not specified
Hematopoietic
* Not specified
Hepatic
* Not specified
Renal
* Not specified
Other
* No psychological, familial, sociological, or geographical condition that would preclude study
* Able to understand the language of the questionnaire
* Mentally fit to complete a questionnaire
PRIOR CONCURRENT THERAPY:
Biologic therapy
* Not specified
Chemotherapy
* Prior chemotherapy allowed
Endocrine therapy
* Not specified
Radiotherapy
* Not specified
Surgery
* Prior surgery for cancer allowed
Other
* No concurrent participation in other quality of life studies that would preclude this study
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
European Organisation for Research and Treatment of Cancer - EORTC
NETWORK
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Anne Bredart
Role: STUDY_CHAIR
Institut Curie
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Institut Jules Bordet
Brussels, , Belgium
Institut Bergonie
Bordeaux, , France
Centre Regional Francois Baclesse
Caen, , France
Institut Curie - Section Medicale
Paris, , France
Centre Paul Strauss
Strasbourg, , France
Centre Alexis Vautrin
Vandœuvre-lès-Nancy, , France
Institut Gustave Roussy
Villejuif, , France
Hospital De Navarra
Pamplona, , Spain
Sahlgrenska University Hospital
Gothenburg, , Sweden
Uppsala University Hospital
Uppsala, , Sweden
Bristol Royal Infirmary
Bristol, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EORTC-15012
Identifier Type: OTHER
Identifier Source: secondary_id
EORTC-15012
Identifier Type: -
Identifier Source: org_study_id